“Vaxxas is developing a needle-free skin patch which delivers the vaccine to the immune cells just below the skin’s surface,” say Munro. “It is potentially a more targeted and efficient wa ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

LYON, France, and BANGKOK, Jan. 17, 2025 /PRNewswire/ -- BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States ...

“Alternative vaccination platforms like Vaxxas’ patch technology can complement traditional needle and syringe delivery, helping us get more vaccines into arms to address emerging health problem ...

PopVax is developing this vaccine in partnership with Germany’s LTS Lohmann Therapie-Systeme AG (LTS), a leading player in transdermal drug delivery. The Patch Forward Prize is a multi-stage $50 ...

The selection by BARDA recognizes Vaxxas’ significant advancements towards commercializing its proprietary high-density microarray patch (HD-MAP) for vaccine delivery, including completion of ...

Vaxxas, a clinical-stage biotechnology company, has announced the appointments of three globally respected vaccine experts as ...

Audicana and colleagues evaluated tolerance to thimerosal-containing vaccines in 125 patients sensitized to mercury derivatives and/or thimerosal. [23] Patch-test results in this patient ...